Clinical trials: Minimal Change Disease
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Minimal Change Disease (MCD)
A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab.
- Trial name
- OBELIX-NS (NCT07710157)
- Testing
- Obinutuzumab Injection, Predniso(lo)ne
- Where
- 6 sites in Austria, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Idiopathic Nephrotic Syndrome (INS)
Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome.
Edema is a major component of nephrotic syndrome (NS), defined by Kidney Disease Improving Global Outcomes (KDIGO) guidelines is, urine protein/creatinine ratio ≥ 2 mg/mg, and hypoalbuminemia ≤ 2.5 g/dl).
- Trial name
- ALB-FFP (NCT07685093)
- Testing
- Human Albumin 20%, Fresh Frozen Plasma
- Volunteers
- 56 people
- Sponsor
- Qamar Shafiq
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Idiopathic Nephrotic Syndrome, Frequently Relapsing Nephrotic Syndrome
Effect of Daily Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) on Proteinuria in Pediatric Patients With Idiopathic Nephrotic Syndrome
This study evaluates the impact of transcutaneous auricular Vagus Nerve stimulation (taVNS) therapy on the incidence of nephrotic syndrome relapses in children with idiopathic nephrotic syndrome.
- Trial name
- taVNS (NCT04169776)
- Testing
- Transcutaneous Auricular Vagus Nerve (taVNS) stimulation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwell Health
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Disease, Chronic Obstructive
Pulmonary Rehabilitation in Functional Outcomes and Its Relationship With Morbidity and Mortality in Patients With COPD
Background: The pulmonary rehabilitation effects on various outcomes of COPD are well known. However, they may be lost over time due to poor adherence to therapy with absence of regular exercise maintenance in long term, disease…
- Trial name
- NCT03692793
- Testing
- Pulmonary rehabilitation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of the State of Santa Catarina
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD).
- Trial name
- NCT01113385
- Testing
- D-Galactose
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's National Research Institute
Nephrotic Syndrome
Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
A multicenter, randomized, study will be performed to evaluate the efficacy of low dose steroid combined with mycophenolic acid (MyforticR) versus high dose steroid in inducing remission in adults with minimal change nephrotic…
- Trial name
- MSN (NCT01197040)
- Testing
- Prednisone, acid mycophenolic (Myfortic)
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis
Patient Acceptable Symptomatic State and Minimal Clinically Important Difference of the Fatigue in Multiple Sclerosis (SeDiF_SEP)
Fatigue is the most common symptom and the most disabling symptom of Multiple Sclerosis, and its inefficient management can be a source of multiple consultations (increase in health costs) and a reduction in productivity (work…
- Trial name
- SeDiF_SEP (NCT03662347)
- Where
- France
- Volunteers
- 2,100 people
- Sponsor
- Central Hospital, Nancy, France
Insomnia Disorder, Cognitive Functioning
Assessing Modified CBTi in Adults With Insomnia Disorder
Cognitive Behavioral Therapy for Insomnia (CBTi) is the gold-standard, first line recommended treatment for insomnia, and has considerably better long-term outcomes than medications.
- Trial name
- NCT06600516
- Testing
- CBTi: Stimulus Control Core, CBTi: Sleep Restriction Core, CBTi: Sleep Compression Core
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Idaho State University
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Nephrotic Syndrome in Children, Minimal Change Disease
taVNS for FRNS in Children
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications.
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05588063)
- Testing
- Transcutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change
CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
CHILDNEPH is a pan-Canadian project to observe clinical care for children with nephrotic syndrome. Previous studies have indicated that there is wide practice variation in how health care providers treat this remitting and…
- Conditions
- Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome，Idiopathic
- Trial name
- CHILDNEPH (NCT03786263)
- Where
- 12 sites in Canada
- Volunteers
- 400 people
- Sponsor
- University of Calgary
Idiopathic Nephrotic Syndrome
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
The purpose of this study is to determine whether 7-valent pneumococcal conjugate vaccine safely induces immune responses and immunological memory in children with idiopathic nephrotic syndrome in remission.
- Trial name
- NCT01346007
- Testing
- 7-valent pneumococcal conjugate vaccine
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.
- Trial name
- NCT02005198
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Novo Nordisk A/S
Multiple Myeloma
Risk-adapted Therapeutic Strategy in +1q NDMM
This real-world, multicenter prospective clinical study is designed to apply our internationally developed prognostic scoring system to guide individualized therapy in +1q newly diagnosed multiple myeloma (NDMM), using minimal…
- Trial name
- NCT07045168
- Testing
- risk-scoring model
- Where
- China
- Volunteers
- 200 people
- Sponsor
- FengYan Jin
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)